Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo

S. 1622, FDA Device Accountability Act of 2016 (CBO Report for Congress)

Premium   Download PDF Now (3 pages)
Congress 114th
Date Requested April 18, 2016
Requested By the Senate Committee on Health, Education, Labor and Pensions
Date Sent July 12, 2016
Description:

S. 1622 would require the Food and Drug Administration (FDA) to train certain employees to determine the least burdensome means for medical device sponsors to demonstrate the effectiveness of a device. S. 1622 would also require the agency’s ombudsman to audit that training, and FDA would be required to revise guidance on addressing approaches clinical laboratories can use to demonstrate a test’s accuracy. CBO estimates that implementing S. 1622 would cost $7 million over the 2017-2021 period, subject to the availability of appropriated funds. Pay-as-you-go procedures do not apply because enacting S. 1622 would not affect direct spending or revenues.

CBO estimates that enacting S. 1622 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2027.

S. 1622 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.

« Return to search CBO reports